360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Bortezomib

Type: Keyphrase

Name: Bortezomib

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Millennium Pharmaceuticals Inc

Millennium Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Study Released

(live-PR.com) - Millennium Pharmaceuticals, Inc. (Millennium) is a bio pharmaceutical company that undertakes research, development, and commercialization activities of medicines used for the treatment of cancer. The company also engages in developing ... [Published Live-PR.com - May 22 2013]

Entities: Millennium Pharmaceuticals Inc, Health Care, Mergers & Acquisitions

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Blood cancers perifosine

AbstractAn important target in cancer treatment is the serine/threonine specific protein kinase Akt, which is involved in the pathway that inhibits apoptosis An important target in cancer treatment is the serine/threonine specific protein kinase Akt, ... [Published Manufacturing Chemist - May 22 2013]

Entities: perifosine, Bortezomib, partial response, dexamethasone

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Array BioPharma's CEO Presents at 2013 UBS Global Life Sciences Conference (Transcript)

Array BioPharma, Inc. (ARRY) 2013 UBS Global Life Sciences Conference Call May 21, 2013 8:30 AM ETAndrew Peterson – UBSHello and good morning. Welcome everyone to the second day of the 2013 UBS Global Life Sciences Conference. My name is Andrew Peterson, ... [Published Seeking Alpha - May 21 2013]

Entities: selumetinib, Patient, Skin Cancer, Carfilzomib, Phase III

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Latest treatments extending survival for multiple myeloma patients

Recent "Spotlight On" report highlights next generation drugsMultiple myeloma is the second most common hematological cancer worldwide, with an estimated 22,000 new cases and over 10,000 deaths expected in the U.S. in 2013 and an approximately equivalent ... [Published Thomson Reuters - May 15 2013]

Entities: Multiple Myeloma, treatments, Velcade, Patient

First reported May 04 2013 - Updated May 04 2013 - 1 reports

Highlights from the European Congress on Hematologic Malignancies

Maria-Victoria Mateos, MD, PhD, consultant physician from the hematology department at University Hospital of Salamanca, Spain, focused on smoldering (asymptomatic) multiple myeloma, specifically advocating early intervention: “The earlier the intervention ... [Published Oncology Times - May 04 2013]

Entities: Lenalidomide, Patient, Ibrutinib, dexamethasone

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Searching for therapeutic synergy in primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because ... [Published Medical Xpress - May 01 2013]

Entities: immunocompromised, Synergism, Vorinostat, Carlos Ramos, B-Cell Lymphoma

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Tokyo Medical University

Drugs and Therapies: Studies from Tokyo Medical University in the Area of Antibiotics Reported

Today's Medical & Research NewsDrugs and Therapies2013 MAY 01 -- By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Drugs and Therapies are presented in a new report. According to news originating from Tokyo, Japan, by NewsRx correspondents, ... [Published NewsRX - May 01 2013]

Entities: Tokyo Medical University, Cytotoxicity, Antibiotics, intracellular, Bortezomib

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Promising new agents for multiple myeloma

Drug development for this type of bone marrow cancer has been gaining momentum, with two new proteasome inhibitor approvals in the last year alone and a number of new treatments in late-stage pipelineMultiple myeloma (also known as myeloma or plasma cell ... [Published PMLive - May 01 2013]

Entities: Multiple Myeloma, dexamethasone, Lenalidomide, Bortezomib

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

ONS: Infection Risk, Prevention, and Management

Laura Zitella, MS, RN, ACNP-BC, AOCN AUDIO: Download podcast (mp3) Laura Zitella is a nurse practitioner in the division of oncology at Stanford Hospital and Clinics in California, and her work has focused for many years on infection management. At the ... [Published Cancernetwork.com - Apr 29 2013]

Entities: Infection, guidelines, Patient, prophylaxis

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Myeloma: ‘Continued Treatment’ Not Maintenance

Carlson, Robert H.NEW YORK CITY—The scientific agenda at the Lymphoma & Myeloma International Congress on Hematologic Malignancies covered extensive ground over three days. The following are some of the take-home messages regarding multiple myeloma:Maintenance ... [Published Oncology Times - Apr 18 2013]

Entities: myeloma, Lenalidomide, Bortezomib

First reported Apr 07 2013 - Updated Apr 07 2013 - 1 reports

Meta-Analysis of VELCADE® (bortezomib)-Based Induction Therapy Followed by Stem-Cell Transplantation Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced data from a meta-analysis of VELCADE-based regimens compared to non-VELCADE-based regimens ... [Published Yahoo! Finance - Apr 07 2013]

Entities: Velcade, induction therapy, Takeda Pharmaceutical Co Ltd, Bortezomib

First reported Dec 10 2012 - Updated Dec 10 2012 - 2 reports

December 10, 2012 Presentations Highlight Data on VELCADE$ (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma

Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma ... [Published Takeda Chemical Industries - Dec 10 2012]

Entities: Velcade, Bortezomib, Multiple Myeloma

Quotes

"We are delighted to welcome Dr. Dixon and Dr. Schenkein to our board," said Nick Leschly, chief bluebird. "Both have demonstrated clear leadership and expertise within their respective fields. Wendy has extensive experience in all aspects of drug commercialization, while David has a proven track record in innovative oncology drug development and hematologic transplantation. Their experiences will be invaluable to bluebird as we advance multiple gene therapy programs towards the market."

bluebird bio Appoints Two New Members to Its Board of Directors Wendy Dixon, Ph.D., and David Sch ... [Published Pharmacy Choice - May 20 2013]

... med. Roy D Baynes, Senior Vice President der Abteilung für Onkologie und Entzündungstherapien bei Gilead Sciences. "Aufgrund dieser vielversprechenden Daten untersuchen wir nun Studiendesigns für die Phase 3 zu Idelalisib als Teil eines Frontline-Behandlungsplans für CLL-Patienten."

Gilead gibt Wirkungsdaten aus Phase-2-Studie zu Idelalisib für nicht vorbehandelte chronische lym ... [Published FinanzNachrichten.de - May 16 2013]

...settings," said Pablo Cagnoni, M D , Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals. "We are committed to exploring therapies in difficult-to-treat cancers for patients who have limited treatment options."

ONYX PHARMACEUTICALS, INC.: Onyx Pharmaceuticals Announces Data Presentations at 49th American So ... [Published 4 Traders - May 15 2013]

Ron Squarer, Chief Executive Officer of Array, noted, "With the recent Phase 3 announcements regarding Array-invented MEK inhibitors, MEK162 and selumetinib, and continuing progress with our wholly-owned hematology-oncology programs, we continue to deliver on our stated objective to become a late-stage development company focused in oncology."

Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013 [Published NewsBlaze - May 06 2013]

More Content

sort by: Date \| Relevance
A closer look at vitamin injections [Published Science-Based Medicine - May 24 2013]
Mesenchymal Stem Cells as Vectors for Lung Canc... [Published Sexual Development - May 23 2013]
Millennium Pharmaceuticals, Inc.: New Millenniu... [Published TransWorldNews - May 22 2013]
Millennium Pharmaceuticals, Inc. - Pharmaceutic... [Published Live-PR.com - May 22 2013]
Blood cancers perifosine [Published Manufacturing Chemist - May 22 2013]
Onyx Pharmaceuticals, Inc. Presents at UBS Glob... [Published Seeking Alpha - May 22 2013]
Array BioPharma's CEO Presents at 2013 UBS Glob... [Published Seeking Alpha - May 21 2013]
Acetylon Pharmaceuticals to Present at UBS Glob... [Published Business Wire - May 20 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Pharmacy Choice - May 20 2013]
Millennium Pharmaceuticals, Inc. - Pharmaceutic... [Published TransWorldNews - May 17 2013]
Gilead gibt Wirkungsdaten aus Phase-2-Studie zu... [Published FinanzNachrichten.de - May 16 2013]
Gilead announces response data from Phase 2 stu... [Published European Pharmaceutical Review - May 16 2013]
Cancer Metabolism as a Therapeutic Target [Published Cancernetwork.com - May 16 2013]
ONYX PHARMACEUTICALS, INC.: Onyx Pharmaceutical... [Published 4 Traders - May 15 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Equities.com - May 15 2013]
Cellular Garbage Disposals Clean Up [Published LiveScience.com - May 15 2013]
Latest treatments extending survival for multip... [Published Thomson Reuters - May 15 2013]
Senesco Announces Presentation on Combination T... [Published Business Wire Health News - May 14 2013]
Part 2: Will Array BioPharma Become A Late-Stag... [Published Seeking Alpha - May 12 2013]
Standardizing Chemotherapy Orders for CPOE [Published PPP Mag.com - May 09 2013]
Dunsire Out At Millennium/Takeda, Replaced by A... [Published Xconomy - May 09 2013]
1 Casino, 1 Biotech And 1 Sofware Stock With Re... [Published Seeking Alpha - May 09 2013]
Takeda rides out Actos decline as fiscal 2012 s... [Published PMLive - May 09 2013]
Array BioPharma's CEO Discusses Q3 2013 Results... [Published Seeking Alpha - May 07 2013]
Celgene’s Revlimid Approaches FDA Decision For ... [Published BioMedReports - May 07 2013]
Array Biopharma, Inc. (ARRY) Misses Q3 EPS by 4... [Published Street Insider - May 06 2013]
Array BioPharma Reports Financial Results for t... [Published NewsBlaze - May 06 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Business Wire - May 06 2013]
Molecular middleman: Studies of the assembly of... [Published Individual.com - May 06 2013]
Highlights from the European Congress on Hemato... [Published Oncology Times - May 04 2013]

Blogs

sort by: Date \| Relevance
A closer look at vitamin injections [Published Science-Based Medicine - May 24 2013] Vitamins are magic. Especially when they’re injected. Roll up the sleeve, find a vein, insert a needle and watch that colourful concoction flow directly into the bloodstream. It may sound somewhat illicit, but that person infusing it is wearing a white ...
Financings of the Fortnight Keeps Its Dauber Up [Published The IN VIVO Blog - Apr 18 2013] Baseball fanatics out there might remember Roger Craig, a pitcher for the hapless expansion 1962 New York Metropolitans, then much later the manager of several memorable San Francisco Giants teams in the 1980s. As the San Fran skipper, Craig was a ...
4 Healthcare Stock Stories to Spark Investment ... [Published Wall St. Cheat Sheet - Mar 11 2013] Boston Scientific Corporation ( NYSE:BSX ): Current price $7.50 The firm reports that preliminary data in the PREVAIL clinical trial attained two out of three co-primary endpoints. The trial evaluates safety and efficacy of the Watchman Left Atrial ...
4 Healthcare Stock Stories to Kick Off the Week [Published Wall St. Cheat Sheet - Feb 11 2013] Cellgene Corporation ( NASDAQ:CELG ): Closing price $100.02 Celgene said Friday that its Pomalyst brand therapy (pomalidomide) for patients suffering from multiple myeloma who have received a minimum of two prior therapies that included lenalidomide ...
Johnson & Johnson Issues Weak Earnings Guidance... [Published Clusterstock - Jan 22 2013] Johnson & Johnson just reported earnings for the fourth quarter of 2012. The market is focused on the weak earnings guidance the company issued for 2013, in the range of $5.35-5.45 per share, below analysts' estimates of $5.49. Revenues in Q4 were ...

Press Releases

sort by: Date \| Relevance
Acetylon Pharmaceuticals to Present at UBS Glob... [Published Business Wire - May 20 2013]
Senesco Announces Presentation on Combination T... [Published Business Wire Health News - May 14 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Business Wire - May 06 2013]
Meta-Analysis of VELCADE® (bortezomib)-Based In... [Published Business Wire Health News - Apr 07 2013]
Prometedores nuevos desarrollos sobre el linfom... [Published PR Newswire - Mar 13 2013]